ATE287270T1 - Verfahren zur herstellung eines arzneimittels zur behandlung des sekundärimmunmangels - Google Patents

Verfahren zur herstellung eines arzneimittels zur behandlung des sekundärimmunmangels

Info

Publication number
ATE287270T1
ATE287270T1 AT95942931T AT95942931T ATE287270T1 AT E287270 T1 ATE287270 T1 AT E287270T1 AT 95942931 T AT95942931 T AT 95942931T AT 95942931 T AT95942931 T AT 95942931T AT E287270 T1 ATE287270 T1 AT E287270T1
Authority
AT
Austria
Prior art keywords
producing
immune deficiency
medicinal product
secondary immune
treating secondary
Prior art date
Application number
AT95942931T
Other languages
English (en)
Inventor
John W Hadden
Original Assignee
Univ South Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ South Florida filed Critical Univ South Florida
Application granted granted Critical
Publication of ATE287270T1 publication Critical patent/ATE287270T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/59—Lectins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT95942931T 1994-11-17 1995-11-16 Verfahren zur herstellung eines arzneimittels zur behandlung des sekundärimmunmangels ATE287270T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34164594A 1994-11-17 1994-11-17
PCT/US1995/015492 WO1996015808A1 (en) 1994-11-17 1995-11-16 Method for making a medicament for treating secondary immunodeficiency

Publications (1)

Publication Number Publication Date
ATE287270T1 true ATE287270T1 (de) 2005-02-15

Family

ID=23338440

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95942931T ATE287270T1 (de) 1994-11-17 1995-11-16 Verfahren zur herstellung eines arzneimittels zur behandlung des sekundärimmunmangels

Country Status (11)

Country Link
US (1) US5698194A (de)
EP (1) EP0789588B1 (de)
JP (4) JP4440342B2 (de)
AT (1) ATE287270T1 (de)
AU (1) AU694304B2 (de)
CA (1) CA2205430C (de)
DE (1) DE69533941T2 (de)
DK (1) DK0789588T3 (de)
ES (1) ES2236719T3 (de)
PT (1) PT789588E (de)
WO (1) WO1996015808A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3497607B2 (ja) * 1995-05-26 2004-02-16 オリンパス株式会社 接眼光学系及びそれを用いた画像表示装置
US6316257B1 (en) * 1996-03-04 2001-11-13 Targeted Genetics Corporation Modified rapid expansion methods (“modified-REM”) for in vitro propagation of T lymphocytes
DE69810091T2 (de) * 1997-02-21 2003-10-09 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw., Zwijnaarde Verwendung von interleukin-15
AU748467B2 (en) * 1997-10-17 2002-06-06 University Of South Florida Method to diagnose and monitor cellular immune deficiencies
JP2003511696A (ja) * 1999-10-13 2003-03-25 インサイト・ゲノミックス・インコーポレイテッド 多重的サイトカイン分析
US20020150541A1 (en) * 2000-09-12 2002-10-17 Gene Trol Biotherapeutics, Inc. Compositions comprising mixtures of therapeutic proteins and methods of producing the same
US20020150552A1 (en) * 2000-09-12 2002-10-17 Lau Allan S. Compositions comprising mixtures of therapeutic proteins and methods of producing the same
US20030129162A1 (en) * 2000-09-12 2003-07-10 Lau Allan S. Compositions comprising mixtures of therapeutic proteins and methods of producing the same
US20070154399A1 (en) * 2000-10-27 2007-07-05 Hadden John W Immunotherapy for immune suppressed patients
US20060194242A1 (en) * 2000-10-27 2006-08-31 Hadden John W Immunotherapy for immune suppressed patients
US6977072B2 (en) 2000-10-27 2005-12-20 Irx Therapeutics, Inc. Vaccine immunotherapy for immune suppressed patients
US20070031372A1 (en) * 2004-08-05 2007-02-08 Hadden John W Vaccine immunotherapy for immune suppressed patients
US7182942B2 (en) * 2000-10-27 2007-02-27 Irx Therapeutics, Inc. Vaccine immunotherapy for immune suppressed patients
US20070025958A1 (en) 2000-10-27 2007-02-01 Hadden John W Vaccine immunotherapy
WO2003035004A2 (en) * 2001-10-26 2003-05-01 Immuno-Rx, Inc. Immunotherapy for reversing immune suppression
US6896879B2 (en) * 2003-07-03 2005-05-24 Cel-Sci Corporation Method of pre-sensitizing cancer prior to treatment with radiation and/or chemotherapy and a novel cytokine mixture
US20050002899A1 (en) * 2003-07-03 2005-01-06 Eyal Talor Method of pre-sensitizing cancer prior to treament with radiation and/or chemotherapy and a novel cytokine mixture
EP1691852A2 (de) * 2003-11-10 2006-08-23 Angiotech International AG Medizinsche implantate und fibroseinduzierende mittel
CN101005760A (zh) * 2004-06-04 2007-07-25 塞尔-赛公司 改变cd4/cd8和进入肿瘤的单核细胞浸润液的方法
ATE513565T1 (de) * 2004-07-30 2011-07-15 Cel Sci Corp Verfahren zum verwalten von cholesterin mit einer serums- und mitogenfreien zytokin-mischung
US20060257357A1 (en) * 2005-05-10 2006-11-16 Cel-Sci Corporation Method for modulating HLA class II tumor cell surface expression with a cytokine mixture
DK2234642T3 (en) 2007-11-28 2018-01-08 Irx Therapeutics Inc PROCEDURE FOR INCREASING AN IMMUNOLOGICAL EFFECT
US8470562B2 (en) * 2008-04-14 2013-06-25 Irx Therapeutics, Inc. IRX-2 modified manufacturing process
JP5797190B2 (ja) 2009-05-15 2015-10-21 アイ アール エックス セーラピューティクス， インコーポレイテッド ワクチン免疫療法
CN103097543A (zh) 2009-12-08 2013-05-08 伊尔克斯治疗有限公司 逆转朗格汉斯细胞免疫抑制的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4390623A (en) * 1980-10-02 1983-06-28 Hooper Trading Company Serum-free and mitogen-free T-cell growth factor and process for making same
US4448879A (en) * 1981-03-26 1984-05-15 Hooper Trading Company High yield process for in vitro production of serum-free and mitogen-free interleukin-2
US4464355A (en) * 1981-03-26 1984-08-07 Hooper Trading Co. Serum-free and mitogen-free T-cell growth factor and process for making same
SE8801426D0 (sv) * 1988-04-15 1988-04-15 Ulf Rothman Forfarande och medel for blodbehandling

Also Published As

Publication number Publication date
JP4440342B2 (ja) 2010-03-24
JP2005245455A (ja) 2005-09-15
EP0789588A1 (de) 1997-08-20
DE69533941T2 (de) 2005-12-29
CA2205430C (en) 2001-09-04
EP0789588B1 (de) 2005-01-19
AU694304B2 (en) 1998-07-16
EP0789588A4 (de) 2001-11-28
PT789588E (pt) 2005-05-31
MX9703626A (es) 1998-12-31
DE69533941D1 (de) 2005-02-24
US5698194A (en) 1997-12-16
ES2236719T3 (es) 2005-07-16
JP2007236395A (ja) 2007-09-20
AU4411196A (en) 1996-06-17
DK0789588T3 (da) 2005-05-30
CA2205430A1 (en) 1996-05-30
WO1996015808A1 (en) 1996-05-30
JPH10510147A (ja) 1998-10-06
JP2009209164A (ja) 2009-09-17

Similar Documents

Publication Publication Date Title
ATE287270T1 (de) Verfahren zur herstellung eines arzneimittels zur behandlung des sekundärimmunmangels
Hunter et al. Histochemical demonstration of enzymes separated by zone electrophoresis in starch gels
AU7769887A (en) Apparatus and methods of culturing motile microorganisms
CA2087525A1 (en) Adoptive immunotherapy with interleukin-7
DE69333433D1 (de) Verfahren zur in vitro kultivierung dendritischer vorläuferzellen und deren verwendung zur immunogen herstellung
KR960009482B1 (en) Method for preserving transplantable sheets of epithelium cultured in vitro
AU4277689A (en) Process for producing cultured epidermal sheet, product and method of use
SG47515A1 (en) Plant gum material and use thereof in food products
EP0340783A3 (en) Apparatus for culturing animal cells, method of culturing thereof and diagnostics of the culture
FR2620131B1 (fr) Procede de production de carotenoides et notamment d'astaxanthine par culture de microalgues et dispositif pour la mise en oeuvre du procede
EP0205387A3 (en) Human monocytes cultured in suspension in serum-free medium
Singer et al. Expression of antigens by cultured epithelial cells: comparison of epidermis and thymic epithelium
Mayyasi et al. Cultivation of L strain (Earle) mouse cells in bacteriological media combined with horse serum
DE3364657D1 (en) Process and apparatus for culture of microorganisms using oxygen-enriched gas
IL88863A0 (en) Method and system for in vitro culture of bovine embryos
Scheicher et al. Recombinant GM-CSF induces in vitro differentiation of dendritic cells from mouse bone marrow
EP0201800A3 (en) A cholesterol-rich fraction, process therefor and use thereof in cell culture
JPS6437282A (en) Method and apparatus for culture of microorganism
EP0299067A4 (de) Zuchtmedium für pflanzen.
GR3031236T3 (en) Process for the preparation of pilocarpine.
PL239589A1 (en) Agent for use reproduction process of cultivable plants by means of tissue culture in vitro and method of increasing reproduction rate of cultivable plants by means of tissue culture in vitro
Evans Thymic reticuloepithelial cell products: role in hematopoietic cell differentiation.
IT1217825B (it) Procedimento ed impianto per la coltura di microorganismi
IL78345A0 (en) Process and apparatus for plant tissue culture propagation
SU1522743A1 (ru) Способ получения аристолохиевых кислот

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0789588

Country of ref document: EP